Visit Pipeline Our Tumor Focus LUNG CANCER Non-small cell lung cancer is considered the most common type of lung cancer, accounting for 85% of all cases,1 while small cell lung cancer makes up approximately 15%.2 In the US there are more than 230,000 new cases of lung cancer and 130...
At EMD Serono, we are passionate about partnering with organizations across all our therapeutic areas to advance our mission of transforming patients’ lives by developing and delivering meaningful therapies for difficult-to-treat diseases. Every year we give generously to support educational activities,...
Merck KGaA, Darmstadt, Germany today shared updates on the company’s oncology pipeline and focused R&D approach Press Releases 23 May 2024 EMD Serono to Showcase Advances in the Science of Cancer With New Data Presented at ASCO 2024 Data from company- and investigator-sponsored studies include...
Partnering with Mersana allows us to incorporate cutting-edge research and technical excellence to enrich our pipeline.” As part of the agreement, EMD Serono will supply monoclonal antibodies to Mersana, which will be used to build Fleximer-ADCs. The company will lead the clinical development and...
Requesting Early Access If a physician wants to request one of our experimental medicines for a patient with a serious or life-threatening disease or condition the physician should send a request toearlyaccess@emdserono.com. Before doing so, the physician should review our Position Statement on Ea...